These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV. Hum Psychopharmacol; 2005 Jul; 20(5):327-41. PubMed ID: 15912562 [Abstract] [Full Text] [Related]
26. Assessments of suicidality in double-blind, placebo-controlled trials of ziprasidone. Karayal ON, Anway SD, Batzar E, Vanderburg DG. J Clin Psychiatry; 2011 Mar; 72(3):367-75. PubMed ID: 21450154 [Abstract] [Full Text] [Related]
27. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Beasley CM, Koke SC, Nilsson ME, Gonzales JS. Clin Ther; 2000 Nov; 22(11):1319-30. PubMed ID: 11117656 [Abstract] [Full Text] [Related]
28. Mania associated with fluoxetine treatment in adolescents. Venkataraman S, Naylor MW, King CA. J Am Acad Child Adolesc Psychiatry; 1992 Mar; 31(2):276-81. PubMed ID: 1564030 [Abstract] [Full Text] [Related]
29. The efficacy of fluoxetine as an antidepressant in the short and long term. Montgomery SA. Int Clin Psychopharmacol; 1989 Jan; 4 Suppl 1():113-9. PubMed ID: 2644336 [No Abstract] [Full Text] [Related]
30. Reexposure to fluoxetine after serious suicide attempts by three patients: the role of akathisia. Rothschild AJ, Locke CA. J Clin Psychiatry; 1991 Dec; 52(12):491-3. PubMed ID: 1752848 [Abstract] [Full Text] [Related]
31. Suicidality and fluoxetine revisited. Masand P, Dewan M. J Clin Psychiatry; 1992 Mar; 53(3):102-3. PubMed ID: 1548246 [No Abstract] [Full Text] [Related]
32. Controversies in the Pharmacotherapy of Adolescent Depression. Masi G. Curr Pharm Des; 2022 Mar; 28(24):1975-1984. PubMed ID: 35619257 [Abstract] [Full Text] [Related]
33. Increased plasma tricyclic antidepressant concentrations in two patients concurrently treated with fluoxetine. Downs JM, Downs AD, Rosenthal TL, Deal N, Akiskal HS. J Clin Psychiatry; 1989 Jun; 50(6):226-7. PubMed ID: 2785987 [Abstract] [Full Text] [Related]
34. Overview of clinically significant adverse reactions to bupropion. Van Wyck Fleet J, Manberg PJ, Miller LL, Harto-Truax N, Sato T, Fleck RJ, Stern WC, Cato AE. J Clin Psychiatry; 1983 May; 44(5 Pt 2):191-6. PubMed ID: 6406456 [Abstract] [Full Text] [Related]
36. Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder. Tauscher-Wisniewski S, Disch D, Plewes J, Ball S, Beasley CM. Psychol Med; 2007 Nov; 37(11):1585-93. PubMed ID: 17640442 [Abstract] [Full Text] [Related]
37. An overview of fluoxetine in geriatric depression. Feighner JP, Boyer WF, Meredith CH, Hendrickson G. Br J Psychiatry Suppl; 1988 Sep; (3):105-8. PubMed ID: 3074861 [No Abstract] [Full Text] [Related]
38. Fluoxetine not associated with increased aggression in controlled clinical trials. Heiligenstein JH, Beasley CM, Potvin JH. Int Clin Psychopharmacol; 1993 Sep; 8(4):277-80. PubMed ID: 8277148 [Abstract] [Full Text] [Related]
39. Does treatment effect depend on control event rate? Revisiting a meta-analysis of suicidality and antidepressant use in children. Proschan MA, Brittain EH, Fay MP. Clin Trials; 2010 Apr; 7(2):109-17; discussion 118-120. PubMed ID: 20338902 [Abstract] [Full Text] [Related]
40. Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials. Beasley CM, Ball SG, Nilsson ME, Polzer J, Tauscher-Wisniewski S, Plewes J, Acharya N. J Clin Psychopharmacol; 2007 Dec; 27(6):682-6. PubMed ID: 18004137 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]